Core Scientific Highlights AI Infrastructure Momentum but Execution Risks Remain Unaddressed

What happened

Core Scientific's Q4 2025 earnings call emphasized progress in building out AI and high-performance computing infrastructure, with CEO Adam Sullivan noting rising energized capacity and a billing ramp for projects like Quarry and CoreWeave. The company continues to rely on Bitcoin mining as its primary revenue source during this transition, portraying the buildout as a strategic shift. However, SEC filings reveal that the HPC hosting segment is 100% dependent on CoreWeave, with $1.14 billion in committed capex and $899 million reimbursable, creating significant counterparty and timing risks. External reports have documented delays at key sites like Denton, Texas, which undermine management's timeline credibility and highlight execution vulnerabilities. Despite the optimistic rhetoric, the fundamental challenges of customer concentration and capital intensity persist, with no evidence yet of tenant diversification or resolved schedule slippage.

Implication

The earnings call highlights do not alter the core investment thesis, which remains focused on observable proof points like tenant diversification and on-schedule delivery. Capital intensity and reimbursement risks are heightened by the $1.14 billion capex commitment, with liquidity dependent on customer prepayments that may lag. Schedule delays at Denton and other sites, as noted in filings, continue to pressure the credibility needed for a rerating to an AI infrastructure platform. Without a disclosed non-CoreWeave tenant or dated billable megawatt updates, the stock's upside is capped by binary execution and counterparty risks. Maintaining a WAIT rating is justified until upcoming filings provide concrete evidence of reduced concentration and stabilized timelines.

Thesis delta

The news of energized capacity rising is an incremental positive but does not shift the investment thesis, which still requires proof of tenant diversification and delivery milestones. Core Scientific must demonstrate a non-CoreWeave lease and dated billable megawatt progress to mitigate the high downside risks from customer concentration and capex timing. Until these are disclosed, the thesis remains unchanged, with the stock priced on narrative rather than fundamentals.